ATE300941T1 - Pharmazeutische formulierung enthaltend tolterodin sowie ihre verwendung - Google Patents

Pharmazeutische formulierung enthaltend tolterodin sowie ihre verwendung

Info

Publication number
ATE300941T1
ATE300941T1 AT00975092T AT00975092T ATE300941T1 AT E300941 T1 ATE300941 T1 AT E300941T1 AT 00975092 T AT00975092 T AT 00975092T AT 00975092 T AT00975092 T AT 00975092T AT E300941 T1 ATE300941 T1 AT E300941T1
Authority
AT
Austria
Prior art keywords
pharmaceutical formulation
tolterodine
formulation containing
hours
active ingredient
Prior art date
Application number
AT00975092T
Other languages
English (en)
Inventor
Lisbeth Nilvebrant
Bengt Hallen
Birgitta Olsson
Jan Stroembom
Torkel Gren
Anders Ringberg
Martin Wikberg
Original Assignee
Pfizer Health Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=56290073&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE300941(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from PCT/SE1999/002052 external-priority patent/WO2000027364A1/en
Priority claimed from SE0000782A external-priority patent/SE0000782D0/xx
Application filed by Pfizer Health Ab filed Critical Pfizer Health Ab
Application granted granted Critical
Publication of ATE300941T1 publication Critical patent/ATE300941T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT00975092T 1999-11-11 2000-10-24 Pharmazeutische formulierung enthaltend tolterodin sowie ihre verwendung ATE300941T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/SE1999/002052 WO2000027364A1 (en) 1998-11-11 1999-11-11 New controlled release bead, a method of producing the same and multiple unit formulation comprising it
SE0000782A SE0000782D0 (sv) 1999-11-11 2000-03-09 Pharmaceutical formulation and its use
PCT/SE2000/002061 WO2001034139A1 (en) 1999-11-11 2000-10-24 Pharmaceutical formulation containing tolterodine and its use

Publications (1)

Publication Number Publication Date
ATE300941T1 true ATE300941T1 (de) 2005-08-15

Family

ID=56290073

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00975092T ATE300941T1 (de) 1999-11-11 2000-10-24 Pharmazeutische formulierung enthaltend tolterodin sowie ihre verwendung

Country Status (24)

Country Link
US (1) US6630162B1 (de)
EP (1) EP1227806B1 (de)
JP (1) JP2003513918A (de)
KR (2) KR100838930B1 (de)
CN (1) CN100353935C (de)
AT (1) ATE300941T1 (de)
AU (1) AU784104B2 (de)
BR (1) BR0015346A (de)
CA (1) CA2387973C (de)
CZ (1) CZ304671B6 (de)
DE (1) DE60021749T2 (de)
DK (1) DK1227806T3 (de)
EE (1) EE05191B1 (de)
ES (1) ES2245320T3 (de)
HK (1) HK1054196B (de)
HU (1) HUP0203028A3 (de)
MX (1) MXPA02004574A (de)
NO (1) NO20022264L (de)
NZ (1) NZ518309A (de)
PL (1) PL356166A1 (de)
PT (1) PT1227806E (de)
SI (1) SI1227806T1 (de)
SK (1) SK6412002A3 (de)
WO (1) WO2001034139A1 (de)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0957073A1 (de) 1998-05-12 1999-11-17 Schwarz Pharma Ag 3,3-Diphenylpropylaminderivate
HUP0203028A3 (en) * 1999-11-11 2005-07-28 Pharmacia Ab Pharmaceutical formulation containing tolterodine and its use
US20030152624A1 (en) * 2001-12-20 2003-08-14 Aldrich Dale S. Controlled release dosage form having improved drug release properties
DE10224556A1 (de) * 2002-05-31 2004-01-08 Grünenthal GmbH 1-Dimethylamino- 3-(3-methoxy-phenyl)2-methyl-pentan-3-ol entaltendes Arzneimittel in verschiedenen Formulierungen
EP1424079A1 (de) * 2002-11-27 2004-06-02 Boehringer Ingelheim International GmbH Kombination eines beta-3-Rezeptoragonisten und eines Serotonin und/oder Norepinephrin-Wiederaufnahmeinhibitors
AU2003303041B2 (en) * 2002-12-13 2008-07-24 Warner-Lambert Company Llc Alpha-2-delta ligand to treat lower urinary tract symptoms
MXPA05007767A (es) * 2003-01-22 2006-01-31 Pfizer Health Ab Dosis reducida de tolterodina y otros agentes antimuscarinicos para tratar trastornos urinarios.
SE0300830D0 (sv) * 2003-03-26 2003-03-26 Pharmacia Ab New formulations and use thereof
DE10315917A1 (de) * 2003-04-08 2004-11-18 Schwarz Pharma Ag Hochreine Basen von 3,3-Diphenylpropylaminmonoestern
EP1635795A1 (de) * 2003-05-30 2006-03-22 Ranbaxy Laboratories, Ltd. Pharmazeutische zusammensetzung mit kontrollierter freigabe von tolterodin sowie deren herstellung
WO2005105036A1 (en) * 2004-04-28 2005-11-10 Natco Pharma Limited Controlled release mucoadhesive matrix formulation containing tolterodine and a process for its preparation
EP1629834A1 (de) * 2004-08-27 2006-03-01 KRKA, D.D., Novo Mesto Pharmazeutische Zusammensetzung von Tolterodin mit verzögerter Freisetzung
CN100382794C (zh) * 2004-08-30 2008-04-23 鲁南制药集团股份有限公司 酒石酸托特罗定的分散片剂型
CN1795845B (zh) * 2004-12-23 2010-10-13 李又欣 作为毒蕈碱受体拮抗剂的3，3-二苯基丙胺衍生物注射用缓释微球制剂
CN1330297C (zh) * 2005-07-04 2007-08-08 宛六一 酒石酸托特罗定软胶囊及其制备方法
EP2015735A1 (de) * 2006-04-21 2009-01-21 Synthon B.V. Tolterodin-perlen
CZ298448B6 (cs) * 2006-08-09 2007-10-03 Zentiva, A. S. Farmaceutická kompozice s obsahem tolterodinu
KR100851033B1 (ko) * 2007-02-12 2008-08-12 명문제약주식회사 엘-주석산 톨터로딘 함유 서방성 제제의 제조방법
KR20080094473A (ko) * 2007-04-20 2008-10-23 한국화학연구원 음이온성 지질나노입자 및 이의 제조방법
CL2008001970A1 (es) * 2007-07-03 2009-03-27 Synthon Bv Perla con un nucleo de celulosa microcristalina, un recubrimiento soluble en agua con un polimero vinil pirrolidina, una capa con tolterodina y un aglutinante, y una capa de liberacion controlada con un poliacrilato; proceso para prepararla; forma de dosificacion, util en trastornos urinarios como vejiga hiperactiva.
US8110226B2 (en) * 2007-07-20 2012-02-07 Mylan Pharmaceuticals Inc. Drug formulations having inert sealed cores
US8486452B2 (en) * 2007-07-20 2013-07-16 Mylan Pharmaceuticals Inc. Stabilized tolterodine tartrate formulations
EP2175843B1 (de) 2007-08-08 2014-10-08 Inventia Healthcare Private Limited Tolterodinhaltige zusammensetzungen mit verzögerter freisetzung
EP2231124A1 (de) * 2007-12-20 2010-09-29 Pharmathen S.A. Ein antimuscarinisches mittel und ein netzmittel enthaltende pharmazeutische formulierung mit verzögerter freisetzung sowie verfahren zu ihrer herstellung
US20090192228A1 (en) * 2008-01-28 2009-07-30 Actavis Group Ptc Ehf Controlled-Release Tolterodine Compositions and Methods
US20090214665A1 (en) * 2008-02-26 2009-08-27 Lai Felix S Controlled Release Muscarinic Receptor Antagonist Formulation
WO2010096820A1 (en) * 2009-02-23 2010-08-26 Eurand, Inc. Controlled release compositions comprising anti-cholinergic drugs
US9078830B2 (en) 2009-07-31 2015-07-14 Ranbaxy Laboratories Limited Multi-layered, multiple unit pharmaceutical compositions
BR112012015084A2 (pt) 2009-12-23 2017-03-07 Lupin Ltd composição farmacêutica de liberação lenta de iloperidone
WO2011095388A1 (en) 2010-02-04 2011-08-11 Synthon Bv Tolterodine bead
SG174658A1 (en) 2010-04-01 2011-10-28 Theravida Inc Pharmaceutical formulations for the treatment of overactive bladder
WO2011137054A1 (en) 2010-04-30 2011-11-03 Merck Sharp & Dohme Corp. Novel beta 3 adrenergic receptor agonists
US8392016B2 (en) 2010-06-25 2013-03-05 LNT PM Inc. Adaptive method for manufacturing of complicated shape parts by hot isostatic pressing of powder materials with using irreversibly deformable capsules and inserts
US8940763B2 (en) 2011-05-10 2015-01-27 Theravida, Inc. Combinations of solifenacin and salivary stimulants for the treatment of overactive bladder
US10987313B2 (en) 2013-10-07 2021-04-27 Impax Laboratories, Llc Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof
CN105658211A (zh) 2013-10-07 2016-06-08 怡百克制药公司 左旋多巴和/或左旋多巴的酯的粘膜粘附性、控制释放调配物和其用途
WO2016029215A1 (en) * 2014-08-22 2016-02-25 Medipath, Inc. Compositions and methods for cannabinoid coatings for use in drug delivery
CN108697688A (zh) 2016-01-20 2018-10-23 塞拉维达公司 用于治疗多汗症的方法和组合物
US11986449B2 (en) 2020-12-22 2024-05-21 Amneal Pharmaceuticals Llc Levodopa dosing regimen
KR20230124622A (ko) 2020-12-22 2023-08-25 암닐 파마슈티컬스 엘엘씨 레보도파 투여 요법

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1144911B (it) 1981-03-19 1986-10-29 Pharmatec Spa Composizione farmaceutica a rilascio controllato contenente ibuprofen
US5382600A (en) 1988-01-22 1995-01-17 Pharmacia Aktiebolag 3,3-diphenylpropylamines and pharmaceutical compositions thereof
ZA933349B (en) 1992-05-13 1994-06-15 Alza Corp Transdermal administration of oxybutynin
SE9203318D0 (sv) 1992-11-06 1992-11-06 Kabi Pharmacia Ab Novel 3,3-diphenylpropylamines, their use and preparation
JPH0710745A (ja) * 1993-06-22 1995-01-13 Tanabe Seiyaku Co Ltd 放出開始時間制御型腸デリバリー経口製剤
JP3453186B2 (ja) * 1994-04-14 2003-10-06 共和薬品工業株式会社 徐放性マイクロカプセルおよびその製造方法
SE9402422D0 (sv) 1994-07-08 1994-07-08 Astra Ab New beads for controlled release and a pharmaceutical preparation containing the same
AU7994694A (en) 1994-10-21 1996-05-15 Leiras Oy Controlled release oral delivery system containing oxybutynin
US5567441A (en) 1995-03-24 1996-10-22 Andrx Pharmaceuticals Inc. Diltiazem controlled release formulation
WO1998003067A1 (en) * 1996-07-19 1998-01-29 Gunnar Aberg S(-)-tolterodine in the treatment of urinary and gastrointestinal disorders
WO1998011888A1 (en) 1996-09-19 1998-03-26 American Home Products Corporation Method of treating urinary incontinence
JPH11193271A (ja) * 1997-10-31 1999-07-21 Ss Pharmaceut Co Ltd アリール酢酸アミド誘導体又はその塩及びこれを含有する医薬
UA72189C2 (uk) * 1997-11-17 2005-02-15 Янссен Фармацевтика Н.В. Фармацевтична композиція, що містить водну суспензію субмікронних ефірів 9-гідроксирисперидон жирних кислот
DE69942928D1 (de) * 1998-08-27 2010-12-23 Pfizer Health Ab Therapeutische formulierung zur verabreichung von tolterodin mit kontrollierter freisetzung
SE9803871D0 (sv) * 1998-11-11 1998-11-11 Pharmacia & Upjohn Ab Therapeutic method and formulation
HUP0203028A3 (en) * 1999-11-11 2005-07-28 Pharmacia Ab Pharmaceutical formulation containing tolterodine and its use

Also Published As

Publication number Publication date
DE60021749T2 (de) 2006-04-20
KR100838930B1 (ko) 2008-06-16
HUP0203028A3 (en) 2005-07-28
NO20022264D0 (no) 2002-05-13
MXPA02004574A (es) 2004-09-10
JP2003513918A (ja) 2003-04-15
CN100353935C (zh) 2007-12-12
NZ518309A (en) 2003-05-30
CZ20021617A3 (cs) 2002-11-13
EP1227806A1 (de) 2002-08-07
KR20070091374A (ko) 2007-09-10
BR0015346A (pt) 2002-06-25
SI1227806T1 (sl) 2005-12-31
AU1319201A (en) 2001-06-06
KR20020062302A (ko) 2002-07-25
PT1227806E (pt) 2005-10-31
CA2387973A1 (en) 2001-05-17
NO20022264L (no) 2002-05-13
HK1054196A1 (zh) 2003-11-21
CA2387973C (en) 2009-12-22
DE60021749D1 (de) 2005-09-08
AU784104B2 (en) 2006-02-02
HK1054196B (zh) 2008-08-01
ES2245320T3 (es) 2006-01-01
HUP0203028A2 (hu) 2003-02-28
EE200200245A (et) 2003-06-16
CZ304671B6 (cs) 2014-08-27
WO2001034139A1 (en) 2001-05-17
DK1227806T3 (da) 2005-10-31
CN1420767A (zh) 2003-05-28
SK6412002A3 (en) 2002-09-10
EE05191B1 (et) 2009-08-17
EP1227806B1 (de) 2005-08-03
PL356166A1 (en) 2004-06-14
US6630162B1 (en) 2003-10-07

Similar Documents

Publication Publication Date Title
ATE300941T1 (de) Pharmazeutische formulierung enthaltend tolterodin sowie ihre verwendung
EP1731141A3 (de) Zusammensetzung zur Unterdrückung von Magensäure
LU90956I2 (fr) Metvix principe actif méthylaminolevulinique sous forme d'un selde préférence l'hyhrochlorure méthylaminolevulinique
EP1428821A8 (de) Piperidin-4-ylamine mit analgetischer Wirksamkeit
CA2005986A1 (en) Benzimidazole derivative with gastric acid inhibitory effect and process for its preparation
HUP0100437A2 (hu) Szabályzott felszabadulású gyógyszerkészítmény tolterodin adagolására
AU2003225617A1 (en) Thiadiazolylpiperazine derivatives useful for treating or preventing pain
EP1159964A3 (de) Zusammenstellungen und Methoden zur Förderung der Beweglichkeit des Verdauungstrakts
CA2126611A1 (en) Opiod Formulations Having Extended Controlled Release
AU2002225772A1 (en) Therapeutic agents and methods of use thereof for treating an amyloidogenic disease
MX9504034A (es) Formas de administracion medicamentosas que contienen acido tioctico, o sales solidas del acido tioctico de liberacion y biodisponibilidad mejoradas.
MXPA02005536A (es) Acidos aminopropilfosfinicos novedosos.
ATE424810T1 (de) Ein hydrokolloid und einen celluloseether enthaltende tablette mit verzögerter freisetzung
CL2004001050A1 (es) Compuesto derivado de 3'-[4-oxo-3-{[(ciclopropil o 2,2,2-trifluoroetil)amino]carbonil}-1,8-naftiridin-1(4h)-il]-3-sustituido-1-1'-bifenil-4-il; composicion farmaceutica; y uso en el tratamiento o prevencion de asma, bronquitis cronica, enfermedad pul
WO1999033450A3 (en) Pharmaceutical composition containing sibutramine and orlistat
EP0398720A3 (de) Piperazin-Derivate
CA2005980A1 (en) Benzimidazole derivative with gastric acid inhibitory effect and process for its preparation
CA2438509A1 (en) Use of cyclohexenone derivatives for the manufacture of a medicament in the treatment of dysuria
CA2544432A1 (en) Stable pharmaceutical composition comprising granulocyte-colony stimulating factor
MXPA01012936A (es) Composicion farmaceutica que contiene sibutramina y orlistat.
TR200102087T2 (tr) Yeni morfolinbenzamid tuzları
NO950177L (no) Farmakologisk aktive erivater
SE0000782D0 (sv) Pharmaceutical formulation and its use
WO2001000187A3 (en) Pharmaceutical composition containing sibutramine and a lipase inhibitor
DK0541726T3 (da) Vækstfaktorsammensætninger, fremstilling og anvendelse

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1227806

Country of ref document: EP

RZN Patent revoked